Results 31 to 40 of about 278,007 (254)

European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen   +23 more
wiley   +1 more source

A 62-Year-Old Man With New-Onset Hypertrophic Cardiomyopathy 25 Years After Surgical Remission of Acromegaly

open access: yesCase Reports in Endocrinology
Acromegaly is a rare disease that is caused by a growth hormone (GH) secreting pituitary tumor. This is a case of a 62-year-old man who presented with hypertrophic cardiomyopathy more than 25 years after surgical remission without other known etiologies ...
Ilan Remba-Shapiro   +5 more
doaj   +1 more source

Neuroendocrine Neoplasms of the Gut

open access: yes, 2020
Neuroendocrine neoplasms of the gut are a heterogeneous group of tumors showing different morphological, clinical, prognostic, and molecular features. Currently, these proliferations are classified as “neuroendocrine neoplasms” (NENs), which include two ...
Rindi, Guido   +5 more
core   +1 more source

Solid Pseudopapillary Neoplasm of the Pancreas in Children and Adolescents: Expert Recommendations

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Solid pseudopapillary neoplasm of the pancreas (SPN) is a rare low‐grade malignant exocrine pancreatic tumor, mostly discovered during the second decade of life in females, with a very good prognosis, provided microscopically complete surgical excision is achieved.
Sabine Irtan   +18 more
wiley   +1 more source

Tumor-derived apolipoprotein E confers resistance to temozolomide in pancreatic neuroendocrine tumors

open access: yesCell Death and Disease
Temozolomide (TMZ) is a first-class clinical drug for patients with pancreatic neuroendocrine tumors (pNETs). However, the therapeutic effects of TMZ are limited because of the chemoresistance of pNET cells, which has not been fully elucidated.
Xin Lou   +15 more
doaj   +1 more source

Neuroendocrine Neoplasms of the Breast

open access: yes, 2020
Neuroendocrine differentiation in breast neoplasms has been a matter of discussion since the first description of a neuroendocrine neoplasm (NEN) in this site.
Silvia Uccella   +7 more
core   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

open access: yesFEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression

open access: yesAdvanced Science
Pancreatic neuroendocrine tumors (PanNETs) frequently exhibit loss or reduced expression of the tumor suppressor MEN1, a key regulator of tumor progression and DNA damage response (DDR).
Jianyun Jiang   +11 more
doaj   +1 more source

Sex differences in body composition and association with cardiometabolic risk

open access: yesBiology of Sex Differences, 2018
Background Body composition differs between men and women, with women having proportionally more fat mass and men more muscle mass. Although men and women are both susceptible to obesity, health consequences differ between the sexes.
Melanie Schorr   +6 more
doaj   +1 more source

Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy

open access: yesCells, 2020
The capacity of cancer to adapt to treatment and evolve is a major limitation for targeted therapies. While the role of new acquired mutations is well-established, recent findings indicate that resistance can also arise from subpopulations of tolerant ...
Mirna Swayden   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy